SecBot SecBot
8-K ·Filed Nov 18, 2026

MDLN

Medline Inc.
NEUTRAL
Impact 4/10
Horizondays Processed3d 15h ago SEC0001193125-26-467193
8-K material event: Items 1.01
Actionable Insight • Neutral

The secondary offering by major shareholders (Blackstone, Carlyle, Hellman & Friedman, GIC, ADIA) represents a significant monetization event, but the concurrent $200M repurchase partially offsets the overhang. Monitor the offering close and any subsequent insider selling patterns for further signals.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$37.84
T+0 close · Nov 18, 2026 · via day close
Latest settled
−2.11%
T+1 · $37.04
Vs SPY
+1.53%
α at T+1
Next horizon
T+5
in 5d
  1. T+0 · Nov 19 $37.84entry
  2. T+1 · 2d ago −2.11%α +1.53% · $37.04
  3. T+5 · in 5d Pending
  4. T+20 · in 26d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Medline Inc. disclosed the pricing of a secondary offering of 60 million shares of Class A common stock by selling stockholders at $35.50 per share, expected to net approximately $2.1 billion for the sellers. Concurrently, Medline and Medline Holdings entered into a $200 million share and unit repurchase agreement with the same selling stockholders, repurchasing Class A common stock and Common Units at the offering price. The repurchase is conditioned on the offering's closing, which is expected on November 23, 2026.

Key Facts

  • Secondary offering of 60,000,000 shares of Class A common stock at $35.50 per share
  • Expected net proceeds to selling stockholders of approximately $2.1 billion
  • Underwriters have a 30-day option to purchase up to an additional 9,000,000 shares
  • Medline and Medline Holdings agreed to repurchase $200 million of Class A common stock and Common Units from selling stockholders
  • Repurchase price equals the per share price paid by underwriters in the secondary offering
  • Repurchase is conditioned on closing of the secondary offering; offering is not conditioned on the repurchase
  • Repurchase counts toward Medline's previously announced share repurchase program
  • Medline is not selling any shares and will not receive any proceeds from the offering
  • Offering expected to close on November 23, 2026

Financial Impact

Selling stockholders to receive ~$2.1B in net proceeds from the secondary offering; Medline to repurchase $200M of equity interests at the same price, reducing shares outstanding by approximately 5.6 million shares (based on $35.50 per share).

dilutionshares outstanding

Risk Factors

  • Secondary offering of 60M shares (plus up to 9M option shares) creates near-term overhang, though the $200M repurchase partially offsets
  • Selling stockholders include entities affiliated with Blackstone, Carlyle, Hellman & Friedman, GIC, and ADIA, all of whom (except ADIA) beneficially own more than 5% of Class A common stock
  • Repurchase is conditioned on the offering closing; if the offering fails to close, the repurchase will not occur

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
79% bullish (34 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-467193
Document: mdln-20261116.htm0001193125-26-467193
Document: mdln-ex99_1.htm0001193125-26-467193
Document: 0001193125-26-467193-index-headers.html0001193125-26-467193
Document: 0001193125-26-467193-index.html0001193125-26-467193
Document: 0001193125-26-467193.txt0001193125-26-467193

Track record

34 reports on MDLN

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +17.95% at T+20 after the May 6, 2026 report. 7 of 10 went positive at some point.

Filters
  1. Nov 19, 20262d ago 424B4 Bearish 5/10 Entry $39.04 Now $37.04 +5.12% settles Nov 30
  2. Nov 18, 20263d ago 8-K Neutral 4/10 Viewing Entry $37.84 Now $37.04 −2.11% settles Nov 27
  3. Nov 18, 20264d ago EFFECT Neutral 5/10 Entry $39.16 Now $37.04 −5.41% settles Nov 25
  4. Nov 17, 20264d ago Press Release Bearish 5/10 Entry $39.16 Now $37.04 +5.41% settles Nov 25
  5. Nov 16, 20266d ago Press Release Bearish 5/10 Entry $39.17 Now $37.04 +5.44% settles Nov 23
  6. Nov 16, 20266d ago S-1 Neutral 4/10 Entry $39.17 Now $37.04 −5.44% settles Nov 23
  7. Nov 13, 20268d ago SC 13G Neutral 3/10 Entry $39.17 Now $37.04 −5.44% settles Nov 23
  8. Nov 13, 20268d ago 144 Neutral 2/10 Entry $39.17 Now $37.04 −5.44% settles Nov 23
  9. Nov 6, 202615d ago SC 13G/A Neutral 3/10 Entry $40.71 to $39.17 Now $37.04 −9.01% ▼ −3.78% −2.09% vs SPY
  10. Nov 4, 202618d ago 8-K Neutral 5/10 No price data
Showing 10 of 34

US Market Status

Market Closed · Opens Mon (25h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 18, 2026